Home » Stocks » Baudax Bio

Baudax Bio, Inc. (BXRX)

Stock Price: $3.39 USD 0.06 (1.65%)
Updated Jul 16, 2020 1:45 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 59.47M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 17.57M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $3.39
Previous Close $3.33
Change ($) 0.06
Change (%) 1.65%
Day's Open 3.27
Day's Range 3.27 - 3.39
Day's Volume 201,531
52-Week Range 2.16 - 10.14

More Stats

Market Cap 59.47M
Enterprise Value 21.86M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 17.57M
Float 11.86M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.51M
Short Ratio 2.92
Short % of Float 16.18%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 37.62M
Net Cash / Share 2.14
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -35.77%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(303.84% upside)
Current: 3.39
Target: 13.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-47.07-65.04-48.26
Net Income-32.56-73.67-61.08
Shares Outstanding9.359.35-
Earnings Per Share-3.48-7.88-
Operating Cash Flow-50.04-59.75-43.27
Capital Expenditures-1.48-3.45-1.29
Free Cash Flow-51.53-63.20-44.56
Cash & Equivalents17.740.000.00
Total Debt0.77--
Net Cash / Debt16.970.000.00
Book Value-16.72-68.35-62.46
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Baudax Bio, Inc.
Country United States
Employees 24
CEO Gerri A. Henwood

Stock Information

Ticker Symbol BXRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BXRX


Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.